X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs STERLING BIOTECH - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA STERLING BIOTECH TORRENT PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 27.1 -1.6 - View Chart
P/BV x 5.1 0.1 8,108.2% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 TORRENT PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
STERLING BIOTECH
Dec-13
TORRENT PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,76811 16,836.2%   
Low Rs1,1863 34,870.6%   
Sales per share (Unadj.) Rs346.126.8 1,291.1%  
Earnings per share (Unadj.) Rs55.2-15.0 -368.9%  
Cash flow per share (Unadj.) Rs73.3-5.5 -1,341.9%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.154.9 468.4%  
Shares outstanding (eoy) m169.22267.87 63.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.30.3 1,645.6%   
Avg P/E ratio x26.8-0.5 -5,760.3%  
P/CF ratio (eoy) x20.1-1.3 -1,583.3%  
Price / Book Value ratio x5.70.1 4,536.1%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8871,862 13,422.5%   
No. of employees `00011.81.4 870.1%   
Total wages/salary Rs m9,934547 1,816.8%   
Avg. sales/employee Rs Th4,971.55,303.3 93.7%   
Avg. wages/employee Rs Th843.2403.8 208.8%   
Avg. net profit/employee Rs Th792.4-2,959.0 -26.8%   
INCOME DATA
Net Sales Rs m58,5697,181 815.6%  
Other income Rs m2,23343 5,241.8%   
Total revenues Rs m60,8027,223 841.8%   
Gross profit Rs m13,773947 1,454.5%  
Depreciation Rs m3,0692,543 120.7%   
Interest Rs m2,0564,377 47.0%   
Profit before tax Rs m10,881-5,931 -183.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545-1,924 -80.3%   
Profit after tax Rs m9,336-4,007 -233.0%  
Gross profit margin %23.513.2 178.3%  
Effective tax rate %14.232.4 43.8%   
Net profit margin %15.9-55.8 -28.6%  
BALANCE SHEET DATA
Current assets Rs m53,84114,335 375.6%   
Current liabilities Rs m31,61249,809 63.5%   
Net working cap to sales %38.0-494.0 -7.7%  
Current ratio x1.70.3 591.8%  
Inventory Days Days97403 24.1%  
Debtors Days Days84171 49.1%  
Net fixed assets Rs m42,07955,432 75.9%   
Share capital Rs m846268 315.9%   
"Free" reserves Rs m42,65513,935 306.1%   
Net worth Rs m43,50114,701 295.9%   
Long term debt Rs m22,4089,478 236.4%   
Total assets Rs m101,25073,988 136.8%  
Interest coverage x6.3-0.4 -1,773.0%   
Debt to equity ratio x0.50.6 79.9%  
Sales to assets ratio x0.60.1 596.0%   
Return on assets %11.30.5 2,246.2%  
Return on equity %21.5-27.3 -78.7%  
Return on capital %19.6-6.4 -305.5%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m20,0661,860 1,079.0%   
Fx outflow Rs m5,30425 21,310.2%   
Net fx Rs m14,7621,835 804.5%   
CASH FLOW
From Operations Rs m10,1271,719 589.2%  
From Investments Rs m-7,869-3,148 250.0%  
From Financial Activity Rs m-1,9181,426 -134.5%  
Net Cashflow Rs m212-3 -6,220.6%  

Share Holding

Indian Promoters % 71.5 33.9 210.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.0 -  
FIIs % 12.6 9.9 127.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.8 39.3 22.4%  
Shareholders   26,511 21,482 123.4%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  CIPLA  JUBILANT LIFE SCIENCES  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS